FR 167653 free base

Cat. No.:	HY-18754
CAS No.:	158876-65-4
Molecular Formula:	$C_{24}H_{18}FN_5O_2$
Molecular Weight:	427.43
Target:	p38 MAPK; Autophagy
Pathway:	MAPK/ERK Pathway; Autophagy
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

FR 167653 free base, an orally active and selective p38 MAPK inhibitor, is a potent suppressor of TNF-α and IL-1β production via specific inhibition of p38 MAPK activity. FR 167653 free base is effective in treating inflammation, relieving trauma and ischemia-reperfusion injury in vivo[1][2][3].

In Vivo

FR 167653 free base (32 mg/kg; i.h.; 24-48 hours) significantly decreases the extent of acute tubular necrosis[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Inbred male Balbuc mice (aged 8 weeks)[1]
Dosage:	32 mg/kg
Administration:	Subcutaneous injection; 24-48 hours
Result:	The scores of acute tubular necrosis in FR-167653-treated mice were significantly lower in vehicle-treated mice at 24 and 48 h after ischaemiaureperfusion both in cortex and outer medulla.

REFERENCES

[1]. Furuichi K, et al. Administration of FR167653, a new anti-inflammatory compound, prevents renal ischaemia/reperfusion injury in mice. Nephrol Dial Transplant. 2002 Mar;17(3):399-407.

[2]. Iwata Y, et al. p38 Mitogen-activated protein kinase contributes to autoimmune renal injury in MRL-Fas lpr mice. J Am Soc Nephrol. 2003 Jan;14(1):57-67.

[3]. Kawashima Y, et al. FR167653 attenuates ischemia and reperfusion injury of the rat lung with suppressing p38mitogen-activated protein kinase. J Heart Lung Transplant. 2001 May;20(5):568-74.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA